RT @doctorRBC: SPACING trial: possible to taper TNFi in AxSpA pts in LDA âï¸Tapering of TNFi in axSpA resulted in 88%
Tweet Content
SPACING trial: possible to taper TNFi in AxSpA pts in LDA
⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group
⭐️adalimumab spaced out to q35 days
Abs#OP0138
#EULAR2021 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off